# Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

> **NCT01316315** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nivalis Therapeutics, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Active
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01316315
- **Lead sponsor:** Nivalis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316315, "Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01316315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*